ly3437943 retatrutide triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Women's Cardiovascular effects of Glucagon-like Quantity:Double-Pack ($69)

ly3437943 retatrutide triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Women's Cardiovascular effects of Glucagon-like Quantity:Double-Pack ($69)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists | Cardiovascular Diabetology | Springer Nature Link

The weight reductions were accompanied by cardiometabolic profile improvements: decrease in waist circumference, lower systolic and diastolic blood pressure, improved glycemic control including fasting glucose and HbA1c and lower lipid levels

Women's

Quantity:Double-Pack ($69)

Global News also reports that the US Food and Drug Administration has approved a once‑daily Wegovy pill for weight loss, with Novo Nordisk applying to bring an oral Wegovy formulation to Canada